+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying the effectiveness of NAV-240 compared to a placebo in adults with moderate-to-severe Hidradenitis Suppurativa HS. The main goal is to see how many participants achieve at least a 75% reduction in inflamed skin bumps by Week 16 without an increase in abscesses or draining tunnels. This phase 2a study involves participants who have stable HS and have not responded well to antibiotics. Participants will be randomly assigned to receive one of two doses of NAV-240 or a placebo through intravenous infusions. They will receive the assigned treatment during the study period and attend up to 9 clinic visits over 22 weeks for checkups and tests. Participants will also complete a daily diary to record their skin pain. The study includes monitoring skin lesions and other skin-related outcomes over 16 weeks. During the study, participants will have regular assessments, including lesion counts and skin pain evaluations. Researchers will measure outcomes such as the clinical response of HS, skin pain improvement, quality of life changes, and flare occurrences. Safety and treatment effects will be monitored through clinic visits and participant diaries. The total study duration is about 22 weeks, with the main results assessed at Week 16.

Age: 18Years - 70YearsAll GendersPhase 2
41 locations
C

Actively Recruiting

This research aims to provide continued access to the drug anifrolumab for participants who have completed a previous clinical study and are assessed by the Investigator to still benefit from ongoing treatment. The study focuses on monitoring the long-term safety and tolerability of anifrolumab in people with conditions including Systemic Sclerosis, Cutaneous Lupus, Myopathies, and Systemic Lupus Erythematosus. Participants must have received at least one dose of anifrolumab in the prior study and be considered suitable to continue treatment. Participants will receive anifrolumab in the same form and manner as in the parent trial, which may be via pre-filled syringe, pre-filled pen, or infusion. This is an open-label study without randomization, where all participants continue on anifrolumab until they meet study discontinuation criteria. Those with treatment gaps or on compassionate use can also enroll. The study enrollment visit occurs at the end of the parent study after all safety follow-up assessments are complete. Throughout the study, safety monitoring includes collecting data on serious and non-serious adverse events from the first dose until 12 weeks after the last dose of anifrolumab. Participants will be followed until they discontinue, with ongoing assessments of tolerability. The study duration extends until December 2032, allowing long-term observation of treatment effects and safety.

Age: 5Years - 80YearsAll GendersPhase 3
153 locations